Why Trevi Therapeutics (TRVI) Stock Is Up Today

Trevi Therapeutics (TRVI) is up 11.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be renewed investor interest in Trevi’s Haduvio chronic-cough program as the company participated in the ERS Cough Conference that ran through July 17, 2026. There does not appear to be a major new same-day press release or SEC filing, so part of the move could also reflect momentum buying around its regulatory progress, cash position, and prior analyst target increases.

Details:

Trevi said on June 17 that senior management would attend the ERS Cough Conference in London from July 15 to July 17, putting the company in front of investors and respiratory specialists this week.

Trevi said in May that Haduvio development remains on track across chronic cough indications, with plans for a non-IPF ILD Phase 2b study in the second half of 2026 and an RCC Phase 2b study in 2026.

Trevi also said it completed an April stock offering that brought in about $162 million in net proceeds and extended its expected cash runway into 2030.

Earlier this year, Trevi said it gained FDA alignment on the remaining development program for IPF-related chronic cough, including plans for two pivotal Phase 3 trials, which continues to support the long-term bull case.

Sources:

Trevi Therapeutics Investor Relations, SEC, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive TRVI Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$TRVI Hedge Fund Activity

We have seen 84 institutional investors add shares of $TRVI stock to their portfolio, and 79 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VESTAL POINT CAPITAL, LP added 2,166,504 shares (+inf%) to their portfolio in Q1 2026, for an estimated $25,846,392
WELLINGTON MANAGEMENT GROUP LLP added 1,785,098 shares (+52.4%) to their portfolio in Q1 2026, for an estimated $21,296,219
FMR LLC added 1,538,052 shares (+23.7%) to their portfolio in Q1 2026, for an estimated $18,348,960
ASSENAGON ASSET MANAGEMENT S.A. added 1,525,314 shares (+inf%) to their portfolio in Q2 2026, for an estimated $28,447,106
OCTAGON CAPITAL ADVISORS LP removed 1,330,000 shares (-47.2%) from their portfolio in Q1 2026, for an estimated $15,866,900
CITADEL ADVISORS LLC added 1,048,634 shares (+686.0%) to their portfolio in Q1 2026, for an estimated $12,510,203
POINT72 ASSET MANAGEMENT, L.P. removed 1,000,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,930,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TRVI Analyst Ratings

Wall Street analysts have issued reports on $TRVI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 03/18/2026

To track analyst ratings and price targets for $TRVI, check out Quiver Quantitative's $TRVI forecast page.

$TRVI Price Targets

Multiple analysts have issued price targets for $TRVI recently. We have seen 5 analysts offer price targets for $TRVI in the last 6 months, with a median target of $21.0.

Here are some recent targets:

Serge Belanger from Needham set a target price of $23.0 on 05/20/2026
Brandon Folkes from HC Wainwright & Co. set a target price of $21.0 on 05/06/2026
Jason Kolbert from D. Boral Capital set a target price of $19.0 on 04/17/2026
Debanjana Chatterjee from Jones Trading set a target price of $24.0 on 03/19/2026
Judah Frommer from Morgan Stanley set a target price of $18.0 on 03/18/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.